🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Always impressed w the CAR-T IITs my boss Tanya Dorff City of Hope has done in the #prostatecancer space. Tons of interest in her poster at the #ASCO23 GU poster session - it will be highlighted in the poster discussion today!

Don't miss Cancer at Cedars-Sinai's Howard Sandler chairing an ASCO multidisciplinary, case-based discussion on #prostatecancer imaging. Learn more below. #ASCO23.

Breaking news👉#ASCO2023 ASCO Dr. #KarimFizazi presents the First results from all HRR positive 1st line mCRPC #ProstateCancer patients (n=399)from our phase 3 TALAPRO-2 trial👉Talazoparib + Enza significantly improves rPFS vs Enza (HR 0.45), OS trending well👇OncoAlert

TALAPRO-2 underscores the importance of BRCA-driven prostate CA and HRR-deficient prostate CA. DO THE MOLECULAR TESTING! #ASCO23

Exciting to see rational combinations of 177Lu-PSMA with biological response modifiers. Important to see we can move the mark but we still need to optimize the biology. Timing is important. #ASCO23

Maha Hussain Northwestern presents data on combined abiraterone plus olaparib for HRR+ CRPC - big delta in PFS for combination arm! @asco #GU24

Congrats to the investigators for the latest trial of #ProstateCancer #Immunotherapy. But it’s is very hard to argue against Dr Kim Chi’s points about the limitation of #Contact-2 (Cabo atezo vs NHT) in #mCRPC @asco #GU24 Hard to see this changing practice based on current data

Thoughtful #ProstateCancer study evaluating sequencing of #PARPi & Abi #GU24 small study (n~20) w/ wide CI’s made smaller w/limited cross over Highlights path forward for a larger trials perhaps in a cooperative group to definitively answer this necessary❓of combo vs sequence

These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer

Thank you and congratulations to ⁦Sumanta K. Pal, MD, FASCO⁩ for a great SoCal meeting #SCGU25

Proud to have my DoD Physician Research Award funded! So thankful to all of my mentors and collaborators, who I couldn't have done this without. Cancer at Cedars-Sinai Michael Freeman 🇺🇦🌻🏳️‍🌈🏳️‍⚧️🌴🇨🇦 Hyung Kim Edwin Posadas, MD Stephen Freedland, MD Peter Chen Dolores Di Vizio PCF Science Prostate Cancer Foundation Howard Soule

Proud of our #CedarsSinai #UCLA team for developing a new #liquidbiopsy based on EV subsets- we can make a custom #liquidbiopsy for almost any surface target! Check out our paper! sciencedirect.com/science/articl…

Thanks for welcoming the second generation Feng to ASCO! What’s your #ASCO25 happy dance? Toni Choueiri, MD Nancy Lin, MD Karen Knudsen, MBA PhD Paul Nguyen Adam Dicker Edwin Posadas, MD Katrina Pedersen, MD, MS Josh Lang Pamela Kunz, MD, FASCO Fumiko Ladd Chino, MD, FASCO

Another #ASCO25 happy dance. A celebration of friends, collaboration, and a common purpose to cure cancer.

As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs Did we lower standard to PFS when both agents are approved for mCRPC? 🤔 #ProstateCancer #ASCO25 nature.com/articles/s4158…

Great discussion from Angela Jia: contextualizing these 2 abstracts was key. Love the point of PSMA-PET and STAMPEDE when interpreting this data and contemporary RT approaches for localized PCA #ASCO25

nice job by Michael Ong promoting the need to support TRIPLE-SWTICH… let’s see if acting on this PSA threshold is important. #ASCO25

Amazing what STAMPEDE has done for science: the US needs to do something this important for prostate cancer #ASCO25

Another proud RadOncUH Chair moment to see our soon to be newest faculty SOUMYAJIT ROY being recognized for his statistical brilliance in collaboration with #IRONMAN #ASCO25 ASCO Way to go! Jason Brown Pedro C Barata, MD MSc FACP Jonathan Evan Shoag 🇮🇱🇺🇸 Lee Ponsky JAGarciaMD Dr. Theodoros Teknos

What did I learn at #ASCO2025 ? 1. Increasing intensity of treatment improves PFS& toxicity- still need OS data for shared decision making 2. Powerful new treatments for #ProstateCancer are coming. get patients on trial 3. Get biomarkers on your #ProstateCancer Thanks everyone!